TY - JOUR
KW - buprenorphine/naloxone
KW - Medication for opioid use disorder
KW - Methadone
KW - Overdose
KW - Take-home doses
KW - Urine drug screening
AU - Z. Bouck
AU - A. I. Scheim
AU - T. Gomes
AU - V. Ling
AU - A. Caudarella
AU - D. Werb
A1 - 
AD - Centre on Drug Policy Evaluation, Unity Health Toronto, Toronto, ON, Canada; Epidemiology Division, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.; Centre on Drug Policy Evaluation, Unity Health Toronto, Toronto, ON, Canada; Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, PA, United States.; Ontario Drug Policy Research Network, Unity Health Toronto, Toronto, ON, Canada; ICES, Toronto, ON, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada; Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.; ICES, Toronto, ON, Canada.; Department of Community and Family Medicine, University of Toronto, Toronto, ON, Canada.; Centre on Drug Policy Evaluation, Unity Health Toronto, Toronto, ON, Canada; Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada; Division of Infectious Diseases and Global Public Health, UC San Diego, La Jolla, CA, United States. Electronic address: dwerb@ucsd.edu.
BT - The International journal on drug policy
C5 - Opioids & Substance Use
DO - 10.1016/j.drugpo.2022.103680
JF - The International journal on drug policy
LA - eng
M1 - Journal Article
PB - . Published by Elsevier B.V
PY - 2022
SN - 1873-4758; 0955-3959; 0955-3959
SP - 103680
T1 - Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions
T2 - The International journal on drug policy
TI - Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions
U1 - Opioids & Substance Use
U2 - 35447476
U3 - 10.1016/j.drugpo.2022.103680
VL - 104
VO - 1873-4758; 0955-3959; 0955-3959
Y1 - 2022
Y2 - Apr 13
ER -